

## AstraZeneca

Price 4,076p

A handful of news items to mention

Fair Value 5520p vs. 5550p (+35%)

BUY-Top Picks

We have summarised our thoughts on the consequences on our figures, sentiment and investment case of a two-part deal in China as well as recent data for tremelimumab and lebrikizumab. In all, the financial impact is limited and our FV is reduced by only 30 pence to 5,520p. BUY unchanged.

## ANALYSIS

- Over the past 10 days, AstraZeneca has been directly and indirectly in the news with several of its products and our intention here is to summarise our thoughts about the consequences of this information on our figures, sentiment and investment case.
- The first announcement by AstraZeneca was an agreement with a Chinese company called CMS to sell the commercial rights of Plendil in China. This calcium channel blocker approved for HBP is actually a big drug in China as it represented USD189m or 7.5% of the company's total sales in the country in 2015. AZN will continue to manufacture and supply the medicine to CMS and will receive royalties that we assume will reach approx. 30% in total, on top of an initial payment of USD310m. This payment is to be booked as an externalisation revenue in Q1 2016. A second smaller agreement is attached to the first namely the divestment of ex-US rights of another cv drug called lmdur whose sales were USD57m in 2015. In this case, AZN will receive a one-time payment of USD190m that will be booked in other operating income in Q2. Together the two drugs totalled 1% of group sales. The impact is already factored into guidance for a low to mid single digit revenue decline in 2016 vs. 2015. The group stated that externalisation revenues and other operating income would both grow in 2016 vs 2015 but the origin was largely unknown: here is a first component.
- On the same day actually, AstraZeneca reported that tremelimumab, its investigational CTLA-4 targeting agent, failed to reach the primary endpoint in the DETERMINE phase III trial that was assessing its efficacy in advanced malignant mesothelioma. "Treme" failed to improve OS. Although it is rare (about 20,000 new cases in the US per annum), mesothelioma is devastating and has no approved drug beyond first-line. "Treme" received orphan drug status last year and so there was some hope that it could open the market to the drug as early as next year. That said, it has always been considered that big hopes with "treme" were in combination, notably with durvalumab. All interim results here are very encouraging irrespectively of the PD-L1 status of lung cancer patients. As a consequence of DETERMINE data, we have slightly impacted the sales curve at the beginning and removed the USD30m contribution in 2017 while keeping our probability-adjusted estimates of USD500m in 2022 unchanged. DETERMINE represented a "fast-to-market" route for "treme" that will not materialise. This would have helped physicians become more familiar with the drug before the combination with durva is approved. This should not materially impact 2023 targets.
- The third newsflow item is more indirect and relates to the announcement by Roche that lebrikizumab had mixed results in phase III with only one of the two LAVOLTA studies reaching their primary endpoint of reducing the rate of asthma exacerbations. Filing looks uncertain and commercial perspectives are even more jeopardised in our view, at least in asthma. So now, what does this mean for the very similar IL-13 antibody tralokinumab developed by AZN? The fact that only one in two equally designed trials works is intriguing obviously and may question the target itself and its validity in asthma as STRATOS 1-2 are very similar to LAVOLTA1-2 although the compounds are different and could therefore deliver slightly different results: note in particular that "lebri" was tested in two different doses four weeks apart (on top of ICS+other) when "tralo" is tested only with a 300mcg dose every two weeks (on top of ICS+LABA). It looks fair to us at this point to consider that PoS has declined but may give IL-5 targeting agents a larger audience which is good for Nucale (GSK) but also for "benra" (AZN) whereas Roche has no anti-IL-5 in house. Our 2022 sales estimate for "tralo" was USD330m in 2022 and we keep it unchanged for the moment.

## VALUATION

- The three product-related news items discussed above have a limited combined impact on our FV that we have marginally reduced from GBP5,550 to GBP5,520p. We remain at BUY.

## NEXT CATALYSTS

- March 2016 : SOCRATES phase III results (Brilinta in stroke) - [Click here to download](#)



**Analyst :**  
Eric Le Berrigaud  
33(0) 1 56 68 75 33  
eleberrigaud@bryangarnier.com

**Sector Team :**  
Mickael Chane Du  
Hugo Solvet


Bloomberg	AZN LN
Reuters	AZN.L
12-month High / Low (p)	4,863 / 3,904
Market Cap (GBPm)	51,530
Ev (BG Estimates) (GBPm)	60,983
Avg. 6m daily volume (000)	2,460
3y EPS CAGR	-1.0%

	1 M	3 M	6 M	31/12/15
Absolute perf.	4.1%	-7.4%	-4.5%	-11.7%
Healthcare	7.4%	-8.3%	-10.2%	-10.7%
DJ Stoxx 600	9.6%	-6.9%	-6.8%	-7.3%

YEnd Dec. (USDm)	2015	2016e	2017e	2018e
Sales	23,641	21,754	21,108	22,510
% change		-8.0%	-3.0%	6.6%
EBITDA	5,937	7,033	6,557	7,254
EBIT	4,114	5,503	5,325	5,719
% change		33.8%	-3.2%	7.4%
Net income	5,390	5,016	4,893	5,226
% change		-6.9%	-2.5%	6.8%

	2015	2016e	2017e	2018e
Operating margin	17.4	25.3	25.2	25.4
Net margin	6.8	11.8	10.9	12.9
ROE	8.6	14.4	13.7	18.3
ROCE	16.2	14.5	12.4	12.9
Gearing	47.7	76.5	88.1	102.1

(USD)	2015	2016e	2017e	2018e
EPS	4.26	3.97	3.87	4.13
% change	-	-6.9%	-2.5%	6.8%
P/E	13.6x	14.6x	15.0x	14.0x
FCF yield (%)	NM	NM	4.5%	3.6%
Dividends (USD)	2.80	2.80	2.80	2.80
Div yield (%)	4.8%	4.8%	4.8%	4.8%
EV/Sales	3.5x	4.0x	4.2x	4.0x
EV/EBITDA	13.8x	12.3x	13.4x	12.3x
EV/EBIT	20.0x	15.8x	16.5x	15.6x



# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

## Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

## Distribution of stock ratings

BUY ratings 64.4%

NEUTRAL ratings 28.1%

SELL ratings 7.4%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Geneva</b>	<b>New Delhi</b>
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudentiel et de		FINMA	
(FCA)	resolution (ACPR)			

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..